James Watson became the second person to have his genome fully sequenced, publishing the results free online. He believed they never should be patented—his own belonged to the world. Read our obituary of the scientist https://t.co/nguMyFNxsW ...

Group 1: Brown Advisory Global Leaders Strategy Overview - Brown Advisory released its second-quarter 2025 investor letter for the Global Leaders Strategy, focusing on long-term performance through a concentrated portfolio of companies that address customer needs and yield good shareholder returns [1] - The strategy outperformed its benchmark during the quarter, primarily due to investment selection in Information Technology and Industrials [1] Group 2: Illumina, Inc. (NASDAQ:ILMN) Performance - Illumina, Inc. is highlighted as a key stock in the investor letter, with a one-month return of 3.10% and a 52-week loss of 21.02%, closing at $102.75 per share on September 19, 2025, with a market capitalization of $15.793 billion [2] - In the second quarter, Illumina generated approximately $1.06 billion in revenue, reaching the upper end of its guidance range, despite a 3% decline compared to Q2 2024 [4] Group 3: Investment Decisions Regarding Illumina, Inc. - Brown Advisory exited its position in Illumina in May due to a combination of regulatory changes, budget cuts from the National Institute of Health in the U.S., a complete import ban on sales into China, and increased competitive risks [3] - The number of hedge funds holding Illumina decreased from 60 to 54 in the second quarter, indicating a decline in popularity among institutional investors [4]

Biodiversity Genomics - A project aiming to sequence the genomes of approximately 35,000 animal, fungi, and plant species in Great Britain and Ireland has achieved significant progress [1] Challenges - The project faces ongoing challenges [1]

Core Points - Illumina, Inc. will release its second quarter 2025 financial results on July 31, 2025, after market close [1] - A conference call will be held on the same day at 1:30 pm Pacific Time to discuss the results [1][2] - The call will be accessible via a live webcast on Illumina's website [2] - A replay of the conference call will be available on Illumina's website for at least 30 days after the event [3] Company Overview - Illumina is a leader in DNA sequencing and array-based technologies, focusing on improving human health through genomic advancements [4] - The company serves various markets including life sciences, oncology, reproductive health, and agriculture [4] - Illumina emphasizes innovation to maintain its position in the global market [4]

Company Developments - Bio-Techne Corporation has opened a new Customer Experience Centre in Düsseldorf, Germany, aimed at enhancing customer service across the EMEA region and supporting long-term growth [1] - The new centre is set to open in the first half of 2026 and will complement the existing Demonstration Laboratory in the UK, chosen for its strategic location in a thriving life sciences sector [2] - The facility will feature a state-of-the-art Demonstration Laboratory showcasing Bio-Techne's full instrument portfolio, including the recently launched Leo System and the COMET spatial biology platform [3] Industry Prospects - The life science market is projected to grow at a compound annual growth rate (CAGR) of 10.28% from 2024 to 2033, driven by technological advancements, demand for personalized medicine, and increased R&D investments [4] Other Developments - Bio-Techne's brand Asuragen has partnered with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit, a new genetic panel for carrier screening research [5] - The company has expanded its RNAscope in situ hybridization probes portfolio to over 70,000 unique probes across more than 450 species, enhancing spatial biology research [6] Competitive Landscape - Competitor QIAGEN N.V. has enhanced its QIAcuity dPCR system, doubling the number of targets analyzed from a single sample, and partnered with Genomics England for the 100,000 Genomes Project [8] - Thermo Fisher Scientific's Olink Explore Platform has been selected for the UK Biobank Pharma Proteomics Project, aiming to analyze over 5,400 proteins from 600,000 samples [9] - Bio-Rad has made advancements in its ddPCR platform and invested in Geneoscopy for a non-invasive colorectal cancer screening test [11]